Stuart Walek, MD
Dermatology · Flower Mound, TXNPI 1124128004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 32.7% of the total. Reporting peaked in 2022 at $337 and has fallen 65.0% since, to $118 in 2025. That places this record below the midpoint for dermatology clinicians in TX, where the typical reported total is $4,085.
Across 46 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$302
- Sun Pharmaceutical Industries Inc.$114
- Sanofi$95
- LEO Pharma Inc.$62
- Incyte Corporation$59
- Lilly USA, LLC$46
- plus $246 from 10 others
What the payments were for
- Food & beverage$924100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $302 |
| Sun Pharmaceutical Industries Inc. | 5 | $114 |
| Sanofi | 4 | $95 |
| LEO Pharma Inc. | 3 | $62 |
| Incyte Corporation | 3 | $59 |
| Lilly USA, LLC | 2 | $46 |
| Amgen | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Merck | 2 | $25 |
| Medtronic | 1 | $23 |
| Pfizer | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $21 |
| Smith+Nephew | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Novartis | 1 | $20 |
| Bristol Myers Squibb | 1 | $14 |
How this compares
$924 in reported general payments places this provider in the 25th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $48,231 |
| Ketoconazole | 74 | $1,712 |
| Triamcinolone Acetonide | 118 | $1,244 |
| Tacrolimus | 11 | $1,189 |
| Metronidazole | 23 | $965 |
| Clobetasol Propionate | 27 | $871 |
| Mupirocin | 85 | $627 |
| Fluocinonide | 19 | $552 |
| Doxycycline Hyclate | 17 | $147 |
| Cephalexin | 20 | $134 |
| Prednisone | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Flower Mound
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.